Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Thomassen, Yvonne E ^a   Van 't Oever, Aart G ^a   Van Oijen, Monique G C T ^a   Wijffels, René H ^b   Van Der Pol, Leo A ^a   Bakker, Wilfried A M ^a  

^a Institute for Translational Vaccinology   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POLIOMYELITIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ERADICATION; DRUG FORMULATION; DRUG QUALITY; DRUG SYNTHESIS; GUINEA PIG; IMMUNOGENICITY; MOUSE; NONHUMAN; POLIOMYELITIS; PROCESS DEVELOPMENT; RABBIT; RAT; REPEATED DRUG DOSE; VACCINATION; VACCINE PRODUCTION; VIRUS CULTURE;

ANIMALS; CERCOPITHECUS AETHIOPS; GUINEA PIGS; MICE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; RABBITS; RATS; VACCINE POTENCY; VERO CELLS;

EID: 84892612809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083374     Document Type: Article

References (43)

1. Salk D, Salk J (1984) Vaccinology of poliomyelitis. Vaccine 2: 59-74. doi:10.1016/S0264-410X(98)90035-4. PubMed: 6099644.
2. Aylward B, Tangermann R (2011) The global polio eradication initiative: Lessons learned and prospects for success. Vaccine 29, Supplement 4: D80-D85. doi:10.1016/j.vaccine.2011.10.005. PubMed: 22486981.
3. Bakker WAM, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MGCT et al. (2011) Inactivated Polio Vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 29: 7188-7196. doi:10.1016/j.vaccine.2011.05.079. PubMed: 21651934.
4. Sabin AB, Boulger LR (1973) History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1: 115-118. doi:10.1016/0092-1157(73)90048-6.
5. WHO (2002) Recommendations for the production and control of poliomyelitis vaccine (inactivated). Technical Report Series No. 910 World Health Organization.
6. WHO (2009) WHO global action plan to minimize poliovirus facility-associated risk after eradication of wild polioviruses and cessation of routine OPV use (Draft 2009). Available: www.polioeradication.org. Accessed 16 September 2013
7. WHO (2004) Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses Addendum, 2003, to the Recommendations for the Production and Quality Control of Poliomyelitis Vaccine (Inactivated). Technical Report Series No.926 World Health Organization.
8. Venczel L, Landry S, Aylward B, Sutter R, Sabow A et al. (2009) Global post-eradication IPV supply and demand assessment: integrated findings commisioned by the Bill & Melinda Gates Foundation and prepared by Oliver Wyman Inc. Available: Available online at: www.polioeradication.org Accessed 16 September 2013
9. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59: 587-635. doi:10.1146/annurev.micro.58. 030603.123625. PubMed: 16153180.
10. van Wezel AL (1967) Growth of cell-strains and primary cells on microcarriers in homogeneous culture. Nature 216: 64-65. doi:10.1038/216064a0. PubMed: 4292963.
11. van Wezel AL, van Herwaarden JA, van de Heuvel-de Rijk EW (1979) Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev Biol Stand 42: 65-69. PubMed: 223923.
12. Thomassen YE, van Sprang ENM, van der Pol LA, Bakker WAM (2010) Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng 107: 96-104. doi:10.1002/bit.22788. PubMed: 20506395.
13. Thomassen YE, van 't Oever AG, Vinke M, Spiekstra A, Wijffels RH et al. (2013) Scale-down of the inactivated polio vaccine production process. Biotechnol Bioeng 110: 1354-1365. doi:10.1002/bit.24798. PubMed: 23192424.
14. Kersten G, Hazendonk T, Beuvery C (1999) Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17: 2059-2066. doi:10.1016/S0264-410X(98)00409-5. PubMed: 10217607.
15. Kreeftenberg H, Hamidi A (2007) Lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries. In: WHO Meeting Report Intellectual Property Rights and Vaccines in Developing Countries, April 19-20, 2004 WHO Document WHO/IVB/0421.
16. Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M (2006) Technology transfer of Sabin-IPV to new developing country markets. Biologicals 34: 155-158. doi:10.1016/j.biologicals.2006.02.011. PubMed: 16650773.
17. van Noort RB (1992) The Children's Vaccine Initiative and vaccine supply: the role of the public sector. Vaccine 10: 909-910. doi:10.1016/0264-410X(92) 90323-C. PubMed: 1471410.
18. Duchene M, Peetermans J, D'Hondt E, Harford N, Fabry L et al. (1990) Production of poliovirus vaccines: past, present, and future. Viral Immunol 3: 243-272. doi:10.1089/vim.1990.3.243. PubMed: 2076176.
19. Verdijk P (2012) Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults. In: Clinicaltrials.gov [internet]: Bethesda (MD): National Library of Medicine (US) 2000-[cited 2013 May 30]. Available: http://clinicaltrials.gov/show/NCT01708720 NLM Identified: NCT01708720.
20. Verdijk P, Rots NY, Van Oijen MGCT, Oberste MS, Boog CJ et al. (2013) Safety and Immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine, 31: 5531-6. doi:10.1016/j.vaccine.2013.09.021. PubMed: 24063976.
21. Thomassen YE, van der Welle JE, van Eikenhorst G, van der Pol LA, Bakker WAM (2012) Transfer of an adherent Vero cell culture method between two different rocking motion type bioreactors with respect to cell growth and metabolic rates. Process Biochem 47: 288-296. doi:10.1016/j.procbio.2011.11.006.
22. ten Have R, Thomassen YE, Hamzink MRJ, Bakker WAM, Nijst OEM et al. (2012) Development of a fast ELISA for quantifying polio D-antigen in in-process samples. Biologicals 40: 84-87. doi:10.1016/j.biologicals.2011.11.004. PubMed: 22154015.
23. Bakker WAM, Thomassen YE, 't Oever AG, Westdijk J, Oijen MGCT et al. (2012) Development of Inactivated Polio Vaccine (IPV) Derived from Attenuated Sabin Strains. Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June. pp. 7-10, (2009)Jenkins N, Barron N, Alves P, editors. Springer Netherlands. pp. 667-670
24. Expert Committee on Biological Standardization (2002) Fifthied report. Recommendations for the production and control of poliomyelitis vaccine (oral). Technical Report Series No.904 World Health Organization. pp. 31-93.
25. WHO (2012) Recommendations to assure the quality, safety and efficacy of live attenuated poliomyelitis vaccine (oral). Replacement of TRS 904, annex 1 and addendum TRS 910, annex 1.
26. van Wezel AL (1985) Monolayer growth systems: homogeneous unit processes. In: RE SpierJB Griffith. Animal Cell Biotechnology. London: Academic Press. pp. 265-282.
27. van Hemert P, Kilburn DG, van Wezel AL (1969) Homogeneous cultivation of animal cells for the production of virus and virus products. Biotechnol Bioeng 11: 875-885. doi:10.1002/bit.260110513. PubMed: 5361174.
28. van Wezel AL (1973) Microcarrier cultures of animal cells. Tissue culture, methods and applications VII Cell propagations on culture supports. New York and London: Academic Press. pp. 372-376.
29. van Wezel AL, van Steenis G, Hannik CA, Cohen H (1978) New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 41: 159-168. PubMed: 223908.
30. van Wezel AL (1971) New trends in the preparation of cell substrates for the production of virus vaccines. Prog Immunobiol Stand 5: 187-192. PubMed: 4349819.
31. European Pharmacopoeia 7.0 Monograph 0214 (2010). Poliomeylitis Vaccine (Inactivated). Strasbourg, France.
32. van Steenis G, van Wezel AL, Sekhuis VM (1981) Potency testing of killed polio vaccine in rats. Dev Biol Stand 47: 119-128. PubMed: 6262142.
33. European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medicinal Products (EMEA/CPMP) (1998). Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95, June 1998).
34. Westdijk J, Koedam P, Barro M, Steil BP, Collin N et al. (2013) Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 31: 1298-1304. doi:10.1016/j.vaccine.2012.12.076. PubMed: 23313617.
35. Bakker WAM, Thomassen YE, van der Pol LA (2010) Scale-down approach for animal-free polio vaccine production. In: T Noll. Cells and Culture; Proceedings of the 20th ESACT Meeting, Dresden, Germany: Springer Netherlands. pp. 541-550
36. Westdijk J, Brugmans D, Martin J, Oever AV, Bakker WA et al. (2011) Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines. Vaccine 29: 3390-3397. doi:10.1016/j.vaccine.2011.02.085. PubMed: 21397718.
37. van Wezel AL, van SG, van der MP, Osterhaus AD (1984) Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 6 Suppl 2: S335-S340. doi:10.1093/clinids/6.Supplement-2.S335. PubMed: 6429814.
38. Vidor E, Plotkin SA (2013) Poliovirus vaccine-inactivated. In: SA PlotkinWA OrensteinPA Offit. Vaccines. 6th ed. Elsevier.
39. WHO (2013) Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec 88: 1-16.
40. Tanimoto T, Murashige N, Hosoda M, Kusumi E, Ono S et al. (2012) Vaccination for whom? Time to reinvigorate Japanese vaccine policy. Lancet 380: 1647. doi:10.1016/S0140-6736(12)61949-7.
41. Liao G, Li R, Li C, Sun M, Li Y et al. (2012) Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial. J Infect Dis 205: 237-243. doi:10.1093/infdis/jir723. PubMed: 22158682.
42. Liao G, Li Y, Li C (2012) The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV). Clinicaltrials.gov [internet]: Bethesda (MD): National Library of Medicine (US) 2000-[cited 2013 May 30]. Available: http://clinicaltrials.gov/show/NCT01510366 NLM Identified: NCT01510366.
43. European Pharmacopoeia 7.0 (2011). Monograph 20616. Tests for extraneous agents in viral vaccines for human use.